Hikma Pharmaceuticals Resumes US Launch of Generic of GSK Asthma Treatment
By Anthony O. Goriainoff
Hikma Pharmaceuticals PLC said Wednesday that it has resumed the
launch of its generic version of GlaxoSmithKline PLC's asthma
treatment, Advair Diskus, in the U.S.
The FTSE 100 pharmaceutical company said the move followed the
Food and Drug Administration's approval of the amendment to its
abbreviated new drug application, submitted in January. The change
reflected enhanced packaging controls required to meet industry
standards adopted since the time of the initial submission.
Write to Anthony O. Goriainoff at
(END) Dow Jones Newswires
April 21, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.